CAJ | 학술논문

目的：明确结直肠癌组织中ABCG2（ATP-binding cassette superfamily G member 2，ABCG2）的表达及其与患者临床病理特征、以伊立替康（CPT-11）为基础化疗疗效的相关性，从而为结直肠癌患者实现个体化治疗提供理论依据。方法：筛选1996年1月至2011年12月于北京大学肿瘤医院行CPT-11化疗的晚期结直肠癌患者，收集患者完整病史资料及肿瘤组织样本。用免疫组织化学的方法检测样本中ABCG2蛋白表达情况。分析ABCG2蛋白表达与患者临床病理特征、CPT-11化疗疗效的相关性。结果：1）免疫组织化学染色显示ABCG2在结直肠癌组织中表达阳性率达93.2%，癌旁正常肠黏膜ABCG2蛋白阳性表达率为43.6%，癌组织较癌旁正常黏膜组织的表达水平明显增高（P<0.05）。ABCG2表达与患者年龄、性别、病理分化程度、病变部位、肝转移均无明显相关性。2）ABCG2蛋白表达与CPT-11化疗疗效无显著相关（P>0.05）。结论：在应用伊立替康为基础方案化疗的结直肠癌患者中，癌组织中ABCG2蛋白表达水平与患者化疗疗效无明显相关。
목적：명학결직장암조직중ABCG2（ATP-binding cassette superfamily G member 2，ABCG2）적표체급기여환자림상병리특정、이이립체강（CPT-11）위기출화료료효적상관성，종이위결직장암환자실현개체화치료제공이론의거。방법：사선1996년1월지2011년12월우북경대학종류의원행CPT-11화료적만기결직장암환자，수집환자완정병사자료급종류조직양본。용면역조직화학적방법검측양본중ABCG2단백표체정황。분석ABCG2단백표체여환자림상병리특정、CPT-11화료료효적상관성。결과：1）면역조직화학염색현시ABCG2재결직장암조직중표체양성솔체93.2%，암방정상장점막ABCG2단백양성표체솔위43.6%，암조직교암방정상점막조직적표체수평명현증고（P<0.05）。ABCG2표체여환자년령、성별、병리분화정도、병변부위、간전이균무명현상관성。2）ABCG2단백표체여CPT-11화료료효무현저상관（P>0.05）。결론：재응용이립체강위기출방안화료적결직장암환자중，암조직중ABCG2단백표체수평여환자화료료효무명현상관。
Objective:To identify the ABCG2 expression levels in colorectal cancer patients and its relationship with clinicopath-ological features and the efficacy of irinotecan-based chemotherapy and to provide further theoretical basis for individualized treatment. Methods:Clinical data and tumor samples from patients with metastatic CRC who have received irinotecan-based chemotherapy at the Department of Gastroenterological Oncology, Peking University Cancer Hospital from January 1996 to December 2011 were collected. The immunohistochemical method was used to detect ABCG2 expression levels both in colorectal carcinoma and tumor-adjacent nor-mal tissues. The correlations of the expression of ABCG2 with clinicopathological features and the efficacy of irinotecan-based chemo-therapy were statistically analyzed. Results:1) Immunohistochemical staining shows that the positive rate of ABCG2 expression in the colorectal cancer samples is 93.2%, which is significantly higher than that in normal colon mucosa at 43.6%(P<0.05). No significant as-sociations were observed between ABCG2 expression and age, gender, tumor differentiation, primary tumor sites, or liver metastasis.(2) ABCG2 expression has no significant correlation with the efficacy of irinotecan-based chemotherapy (P>0.05). Conclusion:ABCG2 expression has no significant correlation with the efficacy of irinotecan chemotherapy in patients with colorectal cancer.